We spent an afternoon together in a modernist mansion in Copenhagen called Domus Hagedorn, which is owned by Novo Nordisk ... s headquarters in Bagsværd, a suburb of Copenhagen. The building ...

As I step into Rajeev Juneja’s office at Mankind Pharma’s Delhi headquarters ... Pharma major Novo Nordisk saw a lot of success with their launch of glucagon-like peptide-1 (GLP-1) drugs ...

Brii Biosciences, a Durham biotechnology company with global headquarters in China ... IMMvention Therapeutix to collaborate with Novo Nordisk on oral therapies for sickle cell, other chronic diseases ...

Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, ...

Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

However, Novo Nordisk (NYSE: NVO), a pioneer in the field ... The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.

Novo Nordisk - which manufactures Wegovy ... without appropriate checks "and the risk to patient safety remains". Image: Pic: Reuters file photo Weight loss jabs, known as GLP-1 receptor agonists ...

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...

However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back the declines of the past ...